How Stereotactic Radiotherapy Changed the Landscape in Cancer Care
Conflicts of Interest
References
- Guckenberger, M.; Andratschke, N.; Alheit, H.; Holy, R.; Moustakis, C.; Nestle, U.; Sauer, O. Definition of stereotactic body radiotherapy: Principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther. Onkol. 2014, 190, 26–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, C.W.; Glatstein, E.; Marks, L.B.; Emami, B.; Grimm, J.; Sperduto, P.W.; Kim, M.S.; Hui, S.; Dusenbery, K.E.; Cho, L.C. Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect cell death. Int. J. Radiat. Oncol. Biol. Phys. 2021, 110, 21–34. [Google Scholar] [CrossRef] [PubMed]
- Kishan, A.U.; Dang, A.; Katz, A.J.; Mantz, C.A.; Collins, S.P.; Aghdam, N.; Chu, F.I.; Kaplan, I.D.; Appelbaum, L.; Fuller, D.B.; et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw. Open 2019, 2, e188006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brand, D.H.; Tree, A.C.; Ostler, P.; van der Voet, H.; Loblaw, A.; Chu, W.; Ford, D.; Tolan, S.; Jain, S.; Martin, A.; et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019, 20, 1531–1543. [Google Scholar] [CrossRef] [PubMed]
- Schaeffer, E.M.; Srinivas, S.; Adra, N.; An, Y.; Barocas, D.; Bitting, R.; Bryce, A.; Chapin, B.; Cheng, H.H.; Victor, A.D.; et al. NCCN Guidelines Version 1.2023 Prostate Cancer. J. Natl. Compr. Cancer Netw. 2022, 20, 1288–1298. [Google Scholar]
- Chang, J.Y.; Mehran, R.J.; Feng, L.; Verma, V.; Liao, Z.; Welsh, J.W.; Lin, S.H.; O’Reilly, M.S.; Jeter, M.D.; Balter, P.A.; et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (Revised STARS): Long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021, 22, 1448–1457. [Google Scholar] [CrossRef] [PubMed]
- Chang, J.Y.; Senan, S.; Paul, M.A.; Mehran, R.J.; Louie, A.V.; Balter, P.; Groen, H.J.M.; McRae, S.E.; Widder, J.; Feng, L.; et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncol. 2015, 16, 630–637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palma, D.A.; Olson, R.; Harrow, S.; Gaede, S.; Louie, A.V.; Haasbeek, C.; Mulroy, L.; Lock, M.; Rodrigues, G.B.; Yaremko, B.P.; et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial. Lancet 2019, 393, 2051–2058. [Google Scholar] [CrossRef] [PubMed]
- Kinj, R.; Muggeo, E.; Schiappacasse, L.; Bourhis, J.; Herrera, F.G. Stereotactic body radiation therapy in patients with oligometastatic disease: Clinical state of the art and perspectives. Cancers 2022, 14, 1152. [Google Scholar] [CrossRef] [PubMed]
- Hellman, S.; Weichselbaum, R.R. Oligometastases. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1995, 13, 8–10. [Google Scholar] [CrossRef] [PubMed]
- Brown, P.D.; Jaeckle, K.; Ballman, K.V.; Farace, E.; Cerhan, J.H.; Keith Anderson, S.; Carrero, X.W.; Barker, F.G.; Deming, R.; Burri, S.H.; et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial. JAMA 2016, 316, 401–409. [Google Scholar] [CrossRef] [PubMed]
- Chang, W.S.; Kim, H.Y.; Chang, J.W.; Park, Y.G.; Chang, J.H. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: Is stereotactic radiosurgery effective for multiple brain metastases? J. Neurosurg. 2010, 113, 73–78. [Google Scholar] [CrossRef] [PubMed]
- Moreau, J.; Khalil, T.; Dupic, G.; Chautard, E.; Lemaire, J.J.; Magnier, F.; Dedieu, V.; Lapeyre, M.; Verrelle, P.; Biau, J. Second course of stereotactic radiosurgery for locally recurrent brain metastases: Safety and efficacy. PLoS ONE 2018, 13, e0195608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Le Reun, E.; Casutt, A.; Durham, A.; Bouchaab, H.; Romano, E.; Lovis, A.; Krueger, T.; Von Garnier, C.; Özsahin, E.M.; Kinj, R. Lung stereotactic radiation therapy: Intercomparison of irradiation devices in terms of outcome and predictive factors. Cancer/Radiothérapie 2023, 27, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Michalet, M.; Bettaïeb, O.; Khalfi, S.; Ghorbel, A.; Valdenaire, S.; Debuire, P.; Aillères, N.; Draghici, R.; De Méric De Bellefon, M.; Charissoux, M.; et al. Stereotactic MR-guided radiotherapy for adrenal gland metastases: First clinical results. J. Clin. Med. 2023, 12, 291. [Google Scholar] [CrossRef]
- Bordeau, K.; Michalet, M.; Keskes, A.; Valdenaire, S.; Debuire, P.; Cantaloube, M.; Cabaillé, M.; Portales, F.; Draghici, R.; Ychou, M.; et al. Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: Updated results of the montpellier prospective registry study. Cancers 2023, 15, 7. [Google Scholar] [CrossRef]
- Liu, G.; Zhao, L.; Qin, A.; Grills, I.; Deraniyagala, R.; Stevens, C.; Zhang, S.; Yan, D.; Li, X.; Ding, X. Lung Stereotactic Body Radiotherapy (SBRT) using Spot-Scanning Proton Arc (SPArc) therapy: A feasibility study. Front. Oncol. 2021, 11, 664455. [Google Scholar] [CrossRef] [PubMed]
- Hasan, S.; Abel, S.; Verma, V.; Webster, P.; Arscott, W.T.; Wegner, R.E.; Kirichenko, A.; Simone, C.B. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: Practice patterns, outcomes, and the effect of biologically effective dose escalation. J. Gastrointest. Oncol. 2019, 10, 999–1009. [Google Scholar] [CrossRef] [PubMed]
- Theelen, W.S.M.E.; Peulen, H.M.U.; Lalezari, F.; Van Der Noort, V.; De Vries, J.F.; Aerts, J.G.J.V.; Dumoulin, D.W.; Bahce, I.; Niemeijer, A.L.N.; De Langen, A.J.; et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019, 5, 1276–1282. [Google Scholar] [CrossRef] [PubMed]
- Karanam, N.K.; Shang, Z.; Story, M.D.; Timmerman, R.D.; Saha, D. Preclinical evaluation of tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR). Int. J. Radiat. Oncol. Biol. Phys. 2022, 114, e522–e523. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kinj, R.; Bourhis, J. How Stereotactic Radiotherapy Changed the Landscape in Cancer Care. Cancers 2023, 15, 1734. https://doi.org/10.3390/cancers15061734
Kinj R, Bourhis J. How Stereotactic Radiotherapy Changed the Landscape in Cancer Care. Cancers. 2023; 15(6):1734. https://doi.org/10.3390/cancers15061734
Chicago/Turabian StyleKinj, Rémy, and Jean Bourhis. 2023. "How Stereotactic Radiotherapy Changed the Landscape in Cancer Care" Cancers 15, no. 6: 1734. https://doi.org/10.3390/cancers15061734
APA StyleKinj, R., & Bourhis, J. (2023). How Stereotactic Radiotherapy Changed the Landscape in Cancer Care. Cancers, 15(6), 1734. https://doi.org/10.3390/cancers15061734